AU2015292833B2 - Heterocyclic carboxylic acids as activators of soluble guanylate cyclase - Google Patents
Heterocyclic carboxylic acids as activators of soluble guanylate cyclase Download PDFInfo
- Publication number
- AU2015292833B2 AU2015292833B2 AU2015292833A AU2015292833A AU2015292833B2 AU 2015292833 B2 AU2015292833 B2 AU 2015292833B2 AU 2015292833 A AU2015292833 A AU 2015292833A AU 2015292833 A AU2015292833 A AU 2015292833A AU 2015292833 B2 AU2015292833 B2 AU 2015292833B2
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- mixture
- under reduced
- reduced pressure
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- LGPZJQBTRCQVNP-UHFFFAOYSA-N Cc1c(CNCC2)c2cc(O)c1 Chemical compound Cc1c(CNCC2)c2cc(O)c1 LGPZJQBTRCQVNP-UHFFFAOYSA-N 0.000 description 2
- URNOYCYEPKZFAN-UHFFFAOYSA-N CC(C)(C)OC(C(CCN(C1)c2cccc(-c3cccc(C)c3OCc3ccc(CN(CC4)C5CCOCC5)c4c3)n2)C1OC)=O Chemical compound CC(C)(C)OC(C(CCN(C1)c2cccc(-c3cccc(C)c3OCc3ccc(CN(CC4)C5CCOCC5)c4c3)n2)C1OC)=O URNOYCYEPKZFAN-UHFFFAOYSA-N 0.000 description 1
- ADWJBPKDOYFOLZ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)Cc2c1c(F)c(C=O)cc2C)=O Chemical compound CC(C)(C)OC(N(CC1)Cc2c1c(F)c(C=O)cc2C)=O ADWJBPKDOYFOLZ-UHFFFAOYSA-N 0.000 description 1
- PHVWBZKYABEPHZ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)Cc2c1c(F)c(CBr)cc2C)=O Chemical compound CC(C)(C)OC(N(CC1)Cc2c1c(F)c(CBr)cc2C)=O PHVWBZKYABEPHZ-UHFFFAOYSA-N 0.000 description 1
- XCFYMMVVRXUULH-UHFFFAOYSA-N CC(C)(C)OC(N(CCc1c2)Cc1c(C)cc2O)=O Chemical compound CC(C)(C)OC(N(CCc1c2)Cc1c(C)cc2O)=O XCFYMMVVRXUULH-UHFFFAOYSA-N 0.000 description 1
- SAMTUTZFEDHWGZ-UHFFFAOYSA-N CC(C)(C)OC(N(CCc1cc(C)c2)Cc1c2N)=O Chemical compound CC(C)(C)OC(N(CCc1cc(C)c2)Cc1c2N)=O SAMTUTZFEDHWGZ-UHFFFAOYSA-N 0.000 description 1
- KIXBUTFIBMDTDZ-UHFFFAOYSA-N CC(C)(C)OC(N(CCc1cc(OCc2ccccc2)c2)Cc1c2Br)=O Chemical compound CC(C)(C)OC(N(CCc1cc(OCc2ccccc2)c2)Cc1c2Br)=O KIXBUTFIBMDTDZ-UHFFFAOYSA-N 0.000 description 1
- WECLRPFYIKGFIY-SSDOTTSWSA-N CC(C)(C)OC([C@@H]1[IH]CNCC1)=O Chemical compound CC(C)(C)OC([C@@H]1[IH]CNCC1)=O WECLRPFYIKGFIY-SSDOTTSWSA-N 0.000 description 1
- 0 CC(CN(C(*)*1)/C(/C=C/C=*2)=C/C=C2/C2=CC(*)CC(*)=C2OCC2=C*(C)=C(*N(*)C3(CCCC3)CC(C)C3)C3=C(C*)CCC2)C1(*)C(O)=O Chemical compound CC(CN(C(*)*1)/C(/C=C/C=*2)=C/C=C2/C2=CC(*)CC(*)=C2OCC2=C*(C)=C(*N(*)C3(CCCC3)CC(C)C3)C3=C(C*)CCC2)C1(*)C(O)=O 0.000 description 1
- XALGDQALSLWQRH-QIECLKSESA-N CC1NCC(C2)[C@@]12C(OC)=O Chemical compound CC1NCC(C2)[C@@]12C(OC)=O XALGDQALSLWQRH-QIECLKSESA-N 0.000 description 1
- AAUQYAVYRMDOAX-ZANVPECISA-N CCOC([C@@](C1)(C2)[C@@H]1CN2C(OC(C)(C)C)=O)=O Chemical compound CCOC([C@@](C1)(C2)[C@@H]1CN2C(OC(C)(C)C)=O)=O AAUQYAVYRMDOAX-ZANVPECISA-N 0.000 description 1
- UFLBURFPRRPJQT-ZFWWWQNUSA-N CCOC([C@]1(C2)[C@@H]2CN(Cc2ccccc2)C1)=O Chemical compound CCOC([C@]1(C2)[C@@H]2CN(Cc2ccccc2)C1)=O UFLBURFPRRPJQT-ZFWWWQNUSA-N 0.000 description 1
- KYOYTSMQIIGIRI-XPUUQOCRSA-N CCOC([C@]1(C2)[C@@H]2CNC1)=O Chemical compound CCOC([C@]1(C2)[C@@H]2CNC1)=O KYOYTSMQIIGIRI-XPUUQOCRSA-N 0.000 description 1
- YYKBKQGPSYIZMV-IVAZKQEVSA-N CCc1c(CN(CC2)C3CCOCC3)c2cc(COc(c(C)ccc2)c2-c2nc(N(C[C@@H]3C4)C(C[U])[C@]34C(O)=O)ccc2)c1 Chemical compound CCc1c(CN(CC2)C3CCOCC3)c2cc(COc(c(C)ccc2)c2-c2nc(N(C[C@@H]3C4)C(C[U])[C@]34C(O)=O)ccc2)c1 YYKBKQGPSYIZMV-IVAZKQEVSA-N 0.000 description 1
- JEEOZKGYSUUAAU-UHFFFAOYSA-N CCc1c[s]c(C)n1 Chemical compound CCc1c[s]c(C)n1 JEEOZKGYSUUAAU-UHFFFAOYSA-N 0.000 description 1
- CMHINIYKOBMOIE-UHFFFAOYSA-N CCc1cc(C)cc(CC2)c1CN2C(OCC)=O Chemical compound CCc1cc(C)cc(CC2)c1CN2C(OCC)=O CMHINIYKOBMOIE-UHFFFAOYSA-N 0.000 description 1
- RSPRZRQRFKAQCP-JIQYCGOMSA-N COC(C1)C11NC[C@H](C2)C12C(OC)=O Chemical compound COC(C1)C11NC[C@H](C2)C12C(OC)=O RSPRZRQRFKAQCP-JIQYCGOMSA-N 0.000 description 1
- XALGDQALSLWQRH-SHYZEUOFSA-N C[C@@H]1NC[C@@H](C2)[C@]12C(OC)=O Chemical compound C[C@@H]1NC[C@@H](C2)[C@]12C(OC)=O XALGDQALSLWQRH-SHYZEUOFSA-N 0.000 description 1
- JVYAIYMGXVSKHQ-VEEOACQBSA-N Cc(cccc1-c2nc(N(CC[C@H]3C(O)=O)C[C@@H]3OC)ccc2)c1OCc1ccc(CN(CC2)C3CCOCC3)c2c1 Chemical compound Cc(cccc1-c2nc(N(CC[C@H]3C(O)=O)C[C@@H]3OC)ccc2)c1OCc1ccc(CN(CC2)C3CCOCC3)c2c1 JVYAIYMGXVSKHQ-VEEOACQBSA-N 0.000 description 1
- ACOQNTLWSNYZMV-UHFFFAOYSA-N Cc1c(CC(NCC(OC)OC)=O)cccc1OC Chemical compound Cc1c(CC(NCC(OC)OC)=O)cccc1OC ACOQNTLWSNYZMV-UHFFFAOYSA-N 0.000 description 1
- VITXJZAFITXKJF-UHFFFAOYSA-N Cc1c(CC(O)=O)cccc1OC Chemical compound Cc1c(CC(O)=O)cccc1OC VITXJZAFITXKJF-UHFFFAOYSA-N 0.000 description 1
- RMIVTCWUQFBUDQ-SANMLTNESA-N Cc1cccc(-c2c[s]c(N(CCC3)C[C@H]3C(O)=O)n2)c1OCc1cc(CCN(CC2)C3CCOCC3)c2cc1 Chemical compound Cc1cccc(-c2c[s]c(N(CCC3)C[C@H]3C(O)=O)n2)c1OCc1cc(CCN(CC2)C3CCOCC3)c2cc1 RMIVTCWUQFBUDQ-SANMLTNESA-N 0.000 description 1
- XKTHHSRIHHKBRO-ZANKTODISA-N Cc1cccc(-c2nc(N(C[C@H]3C4)[C@@H](C[U])C34C(O)=O)ccc2)c1OCc1cc(C)c(CN(CC2)C3CCOCC3)c2c1 Chemical compound Cc1cccc(-c2nc(N(C[C@H]3C4)[C@@H](C[U])C34C(O)=O)ccc2)c1OCc1cc(C)c(CN(CC2)C3CCOCC3)c2c1 XKTHHSRIHHKBRO-ZANKTODISA-N 0.000 description 1
- PMCOWOCKUQWYRL-UHFFFAOYSA-N Cc1nc(C)ncc1 Chemical compound Cc1nc(C)ncc1 PMCOWOCKUQWYRL-UHFFFAOYSA-N 0.000 description 1
- NCULBGQAGVRLFO-BRJRFNKRSA-N N=NN(CC1C2)C[C@@]12[O]=O Chemical compound N=NN(CC1C2)C[C@@]12[O]=O NCULBGQAGVRLFO-BRJRFNKRSA-N 0.000 description 1
- FHCHFSROLBXHTH-GCZXYKMCSA-N NC1N(Cc2ccccc2)CC(C2)[C@@]12C(O)=O Chemical compound NC1N(Cc2ccccc2)CC(C2)[C@@]12C(O)=O FHCHFSROLBXHTH-GCZXYKMCSA-N 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N O=C1CCOCC1 Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462027376P | 2014-07-22 | 2014-07-22 | |
| US62/027,376 | 2014-07-22 | ||
| PCT/US2015/041245 WO2016014463A1 (en) | 2014-07-22 | 2015-07-21 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015292833A1 AU2015292833A1 (en) | 2016-12-22 |
| AU2015292833B2 true AU2015292833B2 (en) | 2019-11-28 |
Family
ID=53783363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015292833A Ceased AU2015292833B2 (en) | 2014-07-22 | 2015-07-21 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9353090B2 (enExample) |
| EP (1) | EP3172202B1 (enExample) |
| JP (1) | JP6602840B2 (enExample) |
| KR (1) | KR20170035993A (enExample) |
| CN (1) | CN106459017B (enExample) |
| AP (1) | AP2016009615A0 (enExample) |
| AR (1) | AR101265A1 (enExample) |
| AU (1) | AU2015292833B2 (enExample) |
| BR (1) | BR112017000943A2 (enExample) |
| CA (1) | CA2955937A1 (enExample) |
| CL (1) | CL2017000071A1 (enExample) |
| CO (1) | CO2017000438A2 (enExample) |
| DK (1) | DK3172202T3 (enExample) |
| EA (1) | EA032972B1 (enExample) |
| ES (1) | ES2784477T3 (enExample) |
| HU (1) | HUE049231T2 (enExample) |
| IL (1) | IL249587A0 (enExample) |
| MX (1) | MX378717B (enExample) |
| PE (1) | PE20170249A1 (enExample) |
| PH (1) | PH12017500111A1 (enExample) |
| PL (1) | PL3172202T3 (enExample) |
| PT (1) | PT3172202T (enExample) |
| SG (2) | SG10201806565SA (enExample) |
| TW (1) | TWI711615B (enExample) |
| UY (1) | UY36226A (enExample) |
| WO (1) | WO2016014463A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3012001A1 (en) * | 2016-02-01 | 2017-08-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash) |
| CN114773160B (zh) | 2016-09-14 | 2025-03-07 | 基因组股份公司 | 1,3-脂肪二醇化合物和其衍生物 |
| WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| CN106495999B (zh) * | 2016-10-18 | 2019-08-16 | 亳州学院 | 一种芳香醛及其合成方法 |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| UY37808A (es) | 2017-07-14 | 2019-02-28 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos que inhiben la actividad quinasa de la lrrk2 |
| EP4501322A3 (en) * | 2017-08-17 | 2025-04-16 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| US20210230155A1 (en) * | 2018-04-27 | 2021-07-29 | Hetero Labs Limited | Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one |
| CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| JP2021523201A (ja) | 2018-05-15 | 2021-09-02 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US12583816B2 (en) | 2018-10-18 | 2026-03-24 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| WO2020117493A1 (en) | 2018-12-03 | 2020-06-11 | Fmc Corporation | Method for preparing n-phenylpyrazole-1-carboxamides |
| US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| JP7798855B2 (ja) | 2020-07-16 | 2026-01-14 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子に使用するためのカチオン性脂質 |
| CN114957087A (zh) * | 2022-04-13 | 2022-08-30 | 湖南复瑞生物医药技术有限责任公司 | 一种帕罗韦德中间体制备方法 |
| CA3258617A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN WOMEN |
| CN117384082A (zh) * | 2022-07-20 | 2024-01-12 | 杭州国瑞生物科技有限公司 | 一种6,6-二甲基-3-氮杂双环[3.1.0]己烷的合成方法 |
| WO2024097316A1 (en) | 2022-11-04 | 2024-05-10 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators for treating systemic sclerosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122340A1 (en) * | 2011-03-10 | 2012-09-13 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| WO2013025425A1 (en) * | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002214626A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Quaternary amines and related inhibitors of factor xa |
| CA2615426A1 (en) | 2005-07-18 | 2007-01-25 | Bayer Healthcare Ag | Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| AU2008250643A1 (en) | 2007-05-12 | 2008-11-20 | Bayer Schering Pharma Aktiengesellschaft | sGC stimulators, sGC activators and combinations for the treatment of urological disorders |
| CA2698332C (en) | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
| MX2010003071A (es) | 2007-10-05 | 2010-04-01 | Sanofi Aventis Deutschland | Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor. |
| WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| PE20091258A1 (es) | 2007-12-03 | 2009-09-12 | Smithkline Beecham Corp | Derivados de piridina como activadores de la guanilato ciclasa soluble |
| WO2009123316A1 (ja) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
| WO2010015653A1 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| WO2010015652A2 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
| US8741910B2 (en) | 2008-11-25 | 2014-06-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| BRPI1006869A2 (pt) | 2009-01-17 | 2016-03-15 | Bayer Schering Pharma Ag | estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil |
| CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
| WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| KR101793304B1 (ko) | 2010-02-05 | 2017-11-02 | 아드베리오 파마 게엠베하 | 낭성 섬유증의 치료를 위한, 단독으로의 및 ＰＤＥ5 억제제와 조합된 ｓＧＣ 자극제 또는 ｓＧＣ 활성화제 |
| CN103038232B (zh) | 2010-05-26 | 2016-01-20 | 阿德弗里奥药品有限责任公司 | 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途 |
| EP2585055A1 (de) | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| NZ703989A (en) * | 2012-09-07 | 2017-04-28 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
-
2015
- 2015-07-21 WO PCT/US2015/041245 patent/WO2016014463A1/en not_active Ceased
- 2015-07-21 BR BR112017000943A patent/BR112017000943A2/pt not_active Application Discontinuation
- 2015-07-21 US US14/804,363 patent/US9353090B2/en active Active
- 2015-07-21 KR KR1020177004761A patent/KR20170035993A/ko not_active Withdrawn
- 2015-07-21 TW TW104123596A patent/TWI711615B/zh not_active IP Right Cessation
- 2015-07-21 CN CN201580033515.4A patent/CN106459017B/zh active Active
- 2015-07-21 EA EA201790246A patent/EA032972B1/ru not_active IP Right Cessation
- 2015-07-21 ES ES15747311T patent/ES2784477T3/es active Active
- 2015-07-21 JP JP2017503554A patent/JP6602840B2/ja active Active
- 2015-07-21 EP EP15747311.7A patent/EP3172202B1/en active Active
- 2015-07-21 SG SG10201806565SA patent/SG10201806565SA/en unknown
- 2015-07-21 PL PL15747311T patent/PL3172202T3/pl unknown
- 2015-07-21 PT PT157473117T patent/PT3172202T/pt unknown
- 2015-07-21 HU HUE15747311A patent/HUE049231T2/hu unknown
- 2015-07-21 SG SG11201700507XA patent/SG11201700507XA/en unknown
- 2015-07-21 AR ARP150102304A patent/AR101265A1/es unknown
- 2015-07-21 DK DK15747311.7T patent/DK3172202T3/da active
- 2015-07-21 CA CA2955937A patent/CA2955937A1/en not_active Abandoned
- 2015-07-21 MX MX2017000926A patent/MX378717B/es unknown
- 2015-07-21 PE PE2017000087A patent/PE20170249A1/es unknown
- 2015-07-21 AU AU2015292833A patent/AU2015292833B2/en not_active Ceased
- 2015-07-21 AP AP2016009615A patent/AP2016009615A0/en unknown
- 2015-07-22 UY UY0001036226A patent/UY36226A/es unknown
-
2016
- 2016-12-15 IL IL249587A patent/IL249587A0/en unknown
-
2017
- 2017-01-11 CL CL2017000071A patent/CL2017000071A1/es unknown
- 2017-01-18 PH PH12017500111A patent/PH12017500111A1/en unknown
- 2017-01-19 CO CONC2017/0000438A patent/CO2017000438A2/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122340A1 (en) * | 2011-03-10 | 2012-09-13 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| WO2013025425A1 (en) * | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9353090B2 (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
| CN114945566B (zh) | 作为钠通道调节剂的取代四氢呋喃 | |
| EP2892891B1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| CA3150400A1 (en) | Pyridine oxynitride, preparation method therefor and use thereof | |
| ES3062200T3 (en) | Rxfp1 agonists | |
| EP3071205A1 (en) | Benzopiperazine compositions as bet bromodomain inhibitors | |
| EP3617195B1 (en) | Novel tetrahydronaphthyl urea derivatives as inhibitors of tropomyosin receptor kinase a for the treatment of pain | |
| CN115867556A (zh) | Lpa受体拮抗剂及其用途 | |
| KR20170005861A (ko) | 항당뇨병 트리시클릭 화합물 | |
| EP4511114A1 (en) | Heteroaryl compounds for the treatment of pain | |
| KR20240099354A (ko) | Rxfp1 효능제 | |
| CN120641397A (zh) | 稠合吡咯基磺酰胺化合物 | |
| WO2025061141A1 (zh) | 具有改善的药代动力学特性的药物组合物 | |
| WO2012106569A1 (en) | Alpha-ketoheterocycles and methods of making and using | |
| AU2012212088A1 (en) | Alpha-ketoheterocycles and methods of making and using | |
| JP2025501509A (ja) | Ｒｘｆｐ１受容体アゴニストとしてのベンゾチアゾール、ベンゾイソオキサゾールおよびベンゾジオキソールアナログ | |
| WO2022166983A1 (zh) | 杂芳基并哌啶类衍生物及其药物组合物和应用 | |
| CN113272315B (zh) | 一类类固醇化合物及其用途 | |
| JP2011509296A (ja) | イオンチャネルリガンドとしてのアミド誘導体およびそれを使用する薬学的組成物および方法 | |
| CN107820492A (zh) | 作为人类免疫缺陷病毒复制抑制剂的吡啶‑3‑基乙酸衍生物 | |
| AU2015268468A1 (en) | Pyridine derivative | |
| JP2023179389A (ja) | 医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |